#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Palmoplantar pustulosis Systemic lupus erythematosus Usher's syndrome Hypophosphatasia Activated PI3 kinase delta syndrome Deafness bilateral Myotonia Haematological malignancy Small for dates baby Oesophageal carcinoma Gastrointestinal stromal tumour Transferrin decreased Microvillous inclusion disease Prader-Willi syndrome Squamous cell carcinoma of the oral cavity More trials…

    Learn about Rare Diseases

    Pulmonary sarcoidosis – Life with Disease Breast angiosarcoma Myelodysplastic syndrome with excess blasts – Diagnostics Thrombotic thrombocytopenic purpura – Treatment Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome Factor IX deficiency – Basic Information Focal segmental glomerulosclerosis Angiosarcoma metastatic – Basic Information Advanced systemic mastocytosis – Trials in Disease Combined immunodeficiency – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Mk-0482 Corline Heparin Conjugate Ondansetron Hydrochloride Naloxone Sxr1096 Bepirovirsen Amcenestrant Mva-209-Fsp-B4 Clonidine Hydrochloride Zongertinib Cefazolin Burfiralimab Iohexol FLUCLOXACILLIN SODIUM Felis Domesticus (555) Ciltacabtagene Autoleucel Ivonescimab Trimetazidine Dihydrochloride Landiolol Hydrochloride Tanimilast More therapies…

    Learn about Your Condition

    Proteinuria Rectal cancer recurrent Congenital aplastic anaemia Malignant melanoma stage III Paedophilia Lung transplant Skin bacterial infection Hepatitis B Neoplasm malignant Intestinal obstruction Angina pectoris Atrial septal defect Synovial sarcoma Haematological malignancy Hypertonic bladder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

B-cell lymphoma refractory

  • Study of Epcoritamab for Patients with Relapsed, Progressive, or Refractory B-Cell Lymphoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • B-cell lymphoma refractory
    Investigated Drugs:
    • Anakinra
    • Epcoritamab
    • Betamethasone Sodium Phosphate
    Denmark Finland France Germany Italy The Netherlands +3

  • Study on the Safety and Effects of Englumafusp Alfa with Obinutuzumab and Glofitamab for Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • B-cell lymphoma
    • B-cell lymphoma refractory
    Investigated Drugs:
    • Englumafusp Alfa
    • Glofitamab
    • Obinutuzumab
    Belgium Denmark France Italy Spain

  • Study of Axi-Cel, Fludarabine Phosphate, and Cyclophosphamide for Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma Ineligible for Stem Cell Transplant

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • B-cell lymphoma
    • B-cell lymphoma refractory
    Investigated Drugs:
    • Axicabtagene Ciloleucel
    • Fludarabine Phosphate
    • Cyclophosphamide
    France

  • Study on the Safety and Effectiveness of Mosunetuzumab and Atezolizumab for Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • B-cell lymphoma recurrent
    • B-cell lymphoma refractory
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Mosunetuzumab
    • Atezolizumab
    • Tocilizumab
    Germany Spain

  • Study on the Safety and Effectiveness of MB-CART2019.1 for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Levetiracetam
    • Allopurinol
    • Acalabrutinib
    Croatia Hungary
Previous Page
1 2 3

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!